Skip to main content

Navigation group

Type at least 3 characters
993 articles

Articles

Clinical Trial

Published on 06 Mar 2020

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

in Pharmacology of Anti-Cancer Drugs

  • Francesca Urbani
  • Virginia Ferraresi
  • Imerio Capone
  • Iole Macchia
  • Belinda Palermo
  • Carmen Nuzzo
  • Angela Torsello
  • Patrizio Pezzotti
  • Diana Giannarelli
  • Anna Fausta Pozzi
Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study
Frontiers in Oncology
doi 10.3389/fonc.2020.00202
  • 4,464 views
  • 6 citations